Enhanced dissolution and bioavailability of gliclazide using solid dispersion techniques

G. Shavi, Averineni Ranjith Kumar, Y. Usha, K. Armugam, O. Ranjan, K. Ginjupalli, S. Pandey, N. Udupa
{"title":"Enhanced dissolution and bioavailability of gliclazide using solid dispersion techniques","authors":"G. Shavi, Averineni Ranjith Kumar, Y. Usha, K. Armugam, O. Ranjan, K. Ginjupalli, S. Pandey, N. Udupa","doi":"10.5138/IJDD.2010.0975.0215.02011","DOIUrl":null,"url":null,"abstract":"Gliclazide is practically insoluble in water and its bioavailability is limited by dissolution rate. To enhance the dissolution rate and bioavailability the present study was aimed to formulate solid dispersions using different water soluble polymers such as polyethylene glycol 4000 (PEG 4000), polyethylene glycol 6000 (PEG 6000) using fusion method and polyvinyl pyrrolidone K- 30 (PVP K 30) by solvent evaporation method. The interaction of gliclazide with the hydrophilic polymers was studied by Differential Scanning Calorimetry (DSC), Fourier Transformation-Infrared Spectroscopy (FTIR) and X-Ray diffraction analysis. Solid dispersions were characterized for physicochemical properties like drug content, surface morphology and dissolution studies. Various factors like type of polymer and ratio of the drug to polymer on the solubility and dissolution rate of the drug were also evaluated. Pharmacokinetic studies of optimized formulation were compared with pure drug and marketed formulation in wistar rats. The dissolution of the pure drug and solid dispersion prepared with PVP K 30 (1:1) showed 38.3 + 4.5 % and 95 + 5.2 % release respectively within 30 min. Peak plasma concentration of pure drug, solid dispersion (PVP K 30) and marketed formulation was found to be 8.76 + 2.5, 16.04 + 5.5 and 9.24 + 3.6 μg/ml respectively, from these results it was observed that there is two fold increase in peak plasma concentration compared to pure drug. Solid dispersion is an effective technique in increasing solubility, dissolution rate and bioavailability of the poorly soluble drugs. Keywords: Gliclazide; solubility; solid dispersion; pharmacokinetics; peak plasma concentration; half life","PeriodicalId":13912,"journal":{"name":"International Journal of Drug Delivery","volume":"9 1","pages":"49-57"},"PeriodicalIF":0.0000,"publicationDate":"2010-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"47","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Drug Delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5138/IJDD.2010.0975.0215.02011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 47

Abstract

Gliclazide is practically insoluble in water and its bioavailability is limited by dissolution rate. To enhance the dissolution rate and bioavailability the present study was aimed to formulate solid dispersions using different water soluble polymers such as polyethylene glycol 4000 (PEG 4000), polyethylene glycol 6000 (PEG 6000) using fusion method and polyvinyl pyrrolidone K- 30 (PVP K 30) by solvent evaporation method. The interaction of gliclazide with the hydrophilic polymers was studied by Differential Scanning Calorimetry (DSC), Fourier Transformation-Infrared Spectroscopy (FTIR) and X-Ray diffraction analysis. Solid dispersions were characterized for physicochemical properties like drug content, surface morphology and dissolution studies. Various factors like type of polymer and ratio of the drug to polymer on the solubility and dissolution rate of the drug were also evaluated. Pharmacokinetic studies of optimized formulation were compared with pure drug and marketed formulation in wistar rats. The dissolution of the pure drug and solid dispersion prepared with PVP K 30 (1:1) showed 38.3 + 4.5 % and 95 + 5.2 % release respectively within 30 min. Peak plasma concentration of pure drug, solid dispersion (PVP K 30) and marketed formulation was found to be 8.76 + 2.5, 16.04 + 5.5 and 9.24 + 3.6 μg/ml respectively, from these results it was observed that there is two fold increase in peak plasma concentration compared to pure drug. Solid dispersion is an effective technique in increasing solubility, dissolution rate and bioavailability of the poorly soluble drugs. Keywords: Gliclazide; solubility; solid dispersion; pharmacokinetics; peak plasma concentration; half life
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用固体分散技术提高格列齐特的溶出度和生物利用度
格列齐特几乎不溶于水,其生物利用度受溶出率的限制。以聚乙二醇4000 (PEG 4000)、聚乙二醇6000 (PEG 6000)和聚乙烯吡咯烷酮K- 30 (PVP K 30)为原料,采用熔融法制备固体分散体,以提高其溶解速度和生物利用度。采用差示扫描量热法(DSC)、傅里叶变换红外光谱(FTIR)和x射线衍射分析研究了格列齐特与亲水性聚合物的相互作用。研究了固体分散体的理化性质,如药物含量、表面形貌和溶出度。考察了聚合物种类、药物与聚合物的比例等因素对药物溶解度和溶出率的影响。并与纯药及市售制剂在wistar大鼠体内进行了药动学研究。PVP K 30(1:1)制备的纯药和固体分散体在30 min内的释放度分别为38.3 + 4.5%和95 + 5.2%,纯药、固体分散体(PVP K 30)和市售制剂的血药峰浓度分别为8.76 + 2.5、16.04 + 5.5和9.24 + 3.6 μg/ml,与纯药相比,其血药峰浓度提高了2倍。固体分散是提高难溶性药物溶解度、溶出率和生物利用度的有效技术。关键词:格列齐特;溶解度;固体分散;药物动力学;峰值血药浓度;半衰期
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Acridone-based acetylcholinesterase inhibitors: synthesis, antioxidant activity and molecular modeling Limonene and BEZ 235 induce apoptosis in COLO-320 and HCT-116 colon cancer cells Current Aspects and Therapies for Wound healing Formulation, Optimization and Evaluation of Self Emulsifying Immediate Release Tablet of Nebivolol HCl using 32 Factorial Design Particle Size Characterization- Techniques, Factors and Quality-by-design Approach
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1